Skip to main content
White paper

Medicare price negotiation: A paradigm shift in Part D access and cost

Insights from the list of negotiation-eligible drugs in 2026

By Jordan Cates, Katherine M. Holcomb, Jake K. Klaisner, and Ryan Swenson
12 September 2023

About the Author(s)

We’re here to help

Ask the tough questions. We’re ready for them.

popup image